BOULDER, Colorado--NeXstar Pharmaceuticals, Inc., has launched
DaunoXome, its liposomal dauno-rubicin product, as first-line
treatment for advanced HIV-associated Kaposi's sarcoma (KS).
The FDA approved the agent in April, following review of the company's
phase III clinical trial comparing DaunoXome with the ABV regimen
(Adriamycin, bleomycin, vincristine).
The liposomal formulation had comparable efficacy (25% response
rate vs 28% for ABV), the company said, with major safety advantages,
including no significant alopecia, neuropathy, or cardiomyopathy.
"The drug is so well tolerated that patients don't mind coming
back every other week for their treatment," said Dr. Jim
Wernz, of New York University, at a press briefing.